Literature DB >> 18518909

Iron overload in survivors of childhood leukemia after allogeneic hematopoietic stem cell transplantation.

Thirachit Chotsampancharoen1, Kwan Gan, Kimberly A Kasow, Raymond C Barfield, Gregory A Hale, Wing Leung.   

Abstract

Iron overload has not been studied extensively and prospectively in pediatric survivors of allogeneic hematopoietic stem cell transplantation (HSCT); therefore, we conducted a prospective long-term study of 133 survivors of childhood leukemia to assess the incidence of and risk factors for iron overload and to investigate its association with organ dysfunction. One yr after HSCT, the mean serum ferritin level was 1158 ng/mL (range, 22-3264 ng/mL), with 124 patients (93.2%) having a serum ferritin level that exceeded the upper limit of the normal range (110 ng/mL). Thereafter, the serum ferritin level declined over time. There was a positive correlation between the level of serum ferritin and that of total bilirubin (r = 0.21, p < 0.001) and glutamate pyruvate transaminase (r = 0.17, p < 0.001). A high concentration of serum ferritin was associated with low cardiac fractional shortening (r = -0.15, p = 0.047). In addition, patients with hypothyroidism and GH deficiency had a higher level of serum ferritin than those without (p < 0.02). We conclude that iron overload is common after HSCT and is associated with hepatic, cardiac, and endocrine dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18518909     DOI: 10.1111/j.1399-3046.2008.00983.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  10 in total

1.  National Cancer Institute, National Heart, Lung and Blood Institute/Pediatric Blood and Marrow Transplantation Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: the need for pediatric-specific long-term follow-up guidelines.

Authors:  Michael A Pulsipher; Roderick Skinner; George B McDonald; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Clarisa Gracia; Anna Petryk; Smita Bhatia; Nancy Bunin; Michael L Nieder; Christopher C Dvorak; Lillian Sung; Jean E Sanders; Joanne Kurtzberg; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-14       Impact factor: 5.742

2.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

Review 3.  Imaging of late complications of cancer therapy in children.

Authors:  Susan C Shelmerdine; Govind B Chavhan; Paul S Babyn; Paul C Nathan; Sue C Kaste
Journal:  Pediatr Radiol       Date:  2016-12-01

4.  Prevalence and risk factors of iron overload after hematopoietic stem cell transplantation for childhood acute leukemia: a LEA study.

Authors:  A Sirvent; P Auquier; C Oudin; Y Bertrand; S Bohrer; P Chastagner; M Poirée; J Kanold; S Thouvenin; Y Perel; D Plantaz; M-D Tabone; K Yakouben; V Gandemer; P Lutz; N Sirvent; C Vercasson; J Berbis; H Chambost; G Leverger; A Baruchel; G Michel
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

5.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

Review 6.  The role of iron in tumour cell proliferation.

Authors:  Juan Luis Steegmann-Olmedillas
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

7.  Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines.

Authors:  Wendy Landier; Saro H Armenian; Jin Lee; Ola Thomas; F Lennie Wong; Liton Francisco; Claudia Herrera; Clare Kasper; Karla D Wilson; Meghan Zomorodi; Smita Bhatia
Journal:  J Clin Oncol       Date:  2012-10-22       Impact factor: 44.544

8.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

9.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08

10.  Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation.

Authors:  N Jaekel; K Lieder; S Albrecht; O Leismann; K Hubert; G Bug; N Kröger; U Platzbecker; M Stadler; K de Haas; S Altamura; M U Muckenthaler; D Niederwieser; H K Al-Ali
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.